BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil 2017;8:9-37. [PMID: 28490916 DOI: 10.2147/SAR.S109576] [Cited by in Crossref: 97] [Cited by in F6Publishing: 103] [Article Influence: 16.2] [Reference Citation Analysis]
Number Citing Articles
1 Shah S, Schwenk ES, Sondekoppam RV, Clarke H, Zakowski M, Rzasa-Lynn RS, Yeung B, Nicholson K, Schwartz G, Hooten WM, Wallace M, Viscusi ER, Narouze S. ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Reg Anesth Pain Med 2023;48:97-117. [PMID: 36596580 DOI: 10.1136/rapm-2022-104013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nayak SK, Majhi MK, Pradhan BK, Banerjee I, Mohanty S, Pal K. Understanding the suitability of parametric modeling techniques in detecting the changes in the HRV signals acquired from cannabis consuming and nonconsuming Indian paddy-field workers. Advanced Methods in Biomedical Signal Processing and Analysis 2023. [DOI: 10.1016/b978-0-323-85955-4.00009-0] [Reference Citation Analysis]
3 Fraguas-sánchez AI, Torres-suárez AI. Therapeutic uses of Cannabis sativa L. Current state and future perspectives. Current Applications, Approaches, and Potential Perspectives for Hemp 2023. [DOI: 10.1016/b978-0-323-89867-6.00010-x] [Reference Citation Analysis]
4 Csiernik R, Pirie M. A primer on sleeping, dreaming, and psychoactive agents. Journal of Social Work Practice in the Addictions 2022. [DOI: 10.1080/1533256x.2022.2159641] [Reference Citation Analysis]
5 Braatveit KJ, Assmus J, Hove O. Exploring the predictive properties of the Hayes Ability Screening Index subtest background information in identifying individuals with MBID among in-patients with SUD. Front Psychiatry 2022;13:1051946. [PMID: 36590603 DOI: 10.3389/fpsyt.2022.1051946] [Reference Citation Analysis]
6 Ramos B, Santos Martins AF, Lima Osório ES. Psychotic Cannabis Withdrawal: A Clinical Case. Cureus 2022. [DOI: 10.7759/cureus.31465] [Reference Citation Analysis]
7 Lana D, Landucci E, Mazzantini C, Magni G, Pellegrini-giampietro DE, Giovannini MG. The Protective Effect of CBD in a Model of In Vitro Ischemia May Be Mediated by Agonism on TRPV2 Channel and Microglia Activation. IJMS 2022;23:12144. [DOI: 10.3390/ijms232012144] [Reference Citation Analysis]
8 Sullivan RM, Wallace AL, Stinson EA, Montoto KV, Kaiver CM, Wade NE, Lisdahl KM. Assessment of Withdrawal, Mood, and Sleep Inventories After Monitored 3-Week Abstinence in Cannabis-Using Adolescents and Young Adults. Cannabis Cannabinoid Res 2022;7:690-9. [PMID: 34678051 DOI: 10.1089/can.2021.0074] [Reference Citation Analysis]
9 Zabegalov KN, Galstyan DS, Kolesnikova TO, Kositsyn YM, Gubaidullina MA, Maslov GO, Demin KA, Khatsko SL, Kalueff AV. Modeling the drug withdrawal syndrome in zebrafish (<i>Danio rerio</i>). Rev Clin Pharm Drug Ther 2022;20:185-191. [DOI: 10.17816/rcf202185-191] [Reference Citation Analysis]
10 Scott JC. Impact of Adolescent Cannabis Use on Neurocognitive and Brain Development. Child and Adolescent Psychiatric Clinics of North America 2022. [DOI: 10.1016/j.chc.2022.06.002] [Reference Citation Analysis]
11 Tuvel AL, Winiger EA, Ross JM. A Review of the Effects of Adolescent Cannabis Use on Physical Health. Child and Adolescent Psychiatric Clinics of North America 2022. [DOI: 10.1016/j.chc.2022.07.005] [Reference Citation Analysis]
12 Razban M, Exadaktylos AK, Santa VD, Heymann EP. Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department. Int J Emerg Med 2022;15:45. [PMID: 36076180 DOI: 10.1186/s12245-022-00446-0] [Reference Citation Analysis]
13 Durandel L, Sanchez S, Amiot-chapoutot F, Dacunka M, Raoul F, Chapoutot L, Marchais A. Syndrome coronarien aigu et consommation de cannabis ; étude monocentrique rétrospective au Centre Hospitalier de Troyes. Annales de Cardiologie et d'Angéiologie 2022. [DOI: 10.1016/j.ancard.2022.07.006] [Reference Citation Analysis]
14 Gette JA, McKenna KR, McAfee NW, Schumacher JA, Parker JD, Konkle-Parker D. Users of cannabis-only are less likely to accept brief interventions than other substance use profiles in a sample of people living with HIV/AIDS. Am J Addict 2022;31:447-53. [PMID: 35488889 DOI: 10.1111/ajad.13300] [Reference Citation Analysis]
15 Kim J, Reitsma J, Parsh B. CBD. Nursing 2022;52:10-11. [DOI: 10.1097/01.nurse.0000839812.29927.ad] [Reference Citation Analysis]
16 Kurt Tunagur EM, Yazici AB, Guzel D, Tunagur MT, Ermis C, Suda MA, Yazici E. Investigating associations between appetite-regulating hormones, aggression and craving in males with cannabis use disorder. Drug Alcohol Depend 2022;238:109577. [PMID: 35905593 DOI: 10.1016/j.drugalcdep.2022.109577] [Reference Citation Analysis]
17 Connor JP, Stjepanović D, Budney AJ, Le Foll B, Hall WD. Clinical management of cannabis withdrawal. Addiction 2022;117:2075-95. [PMID: 34791767 DOI: 10.1111/add.15743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Badiola I, Doshi A, Narouze S. Cannabis, cannabinoids, and cannabis-based medicines: future research directions for analgesia. Reg Anesth Pain Med 2022;47:437-444. [DOI: 10.1136/rapm-2021-103109] [Reference Citation Analysis]
19 Flannery JS, Riedel MC, Salo T, Hill-Bowen LD, Poudel R, Adams AR, Laird AR, Gonzalez R, Sutherland MT. Interactive Effects of HIV Infection and Cannabis Use on Insula Subregion Functional Connectivity. J Neuroimmune Pharmacol 2022;17:289-304. [PMID: 34427866 DOI: 10.1007/s11481-021-10005-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Erickson SK, Vorwerk ML. A perspective review of cannabis use and sexual offenses. Behav Sci Law 2022. [PMID: 35445434 DOI: 10.1002/bsl.2571] [Reference Citation Analysis]
21 Missig G, Mehta N, Robbins JO, Good CH, Iliopoulos-Tsoutsouvas C, Makriyannis A, Nikas SP, Bergman J, Carlezon WA Jr, Paronis CA. Altered sleep during spontaneous cannabinoid withdrawal in male mice. Behav Pharmacol 2022;33:195-205. [PMID: 35288510 DOI: 10.1097/FBP.0000000000000674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Mills L, Lintzeris N, O'Malley M, Arnold JC, McGregor IS. Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug Alcohol Rev 2022. [PMID: 35172040 DOI: 10.1111/dar.13444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Wallis D, Coatsworth JD, Mennis J, Riggs NR, Zaharakis N, Russell MA, Brown AR, Rayburn S, Radford A, Hale C, Mason MJ. Predicting Self-Medication with Cannabis in Young Adults with Hazardous Cannabis Use. Int J Environ Res Public Health 2022;19:1850. [PMID: 35162872 DOI: 10.3390/ijerph19031850] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
24 Romero-Sanchiz P, Mahu IT, Barrett SP, Salmon JP, Al-Hamdani M, Swansburg JE, Stewart SH. Craving and emotional responses to trauma and cannabis cues in trauma-exposed cannabis users: Influence of PTSD symptom severity. Addict Behav 2022;125:107126. [PMID: 34655908 DOI: 10.1016/j.addbeh.2021.107126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Laudanski K, Wain J. Considerations for Cannabinoids in Perioperative Care by Anesthesiologists. J Clin Med 2022;11:558. [PMID: 35160010 DOI: 10.3390/jcm11030558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Nazarov O, Li G. Linking Cannabis and Homicide: Comparison with Alcohol. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-67928-6_77-1] [Reference Citation Analysis]
27 Murray H, Thant T. Cannabis in the Adult Medical and Consultation-Liaison Settings. Cannabis in Psychiatric Practice 2022. [DOI: 10.1007/978-3-031-04874-6_14] [Reference Citation Analysis]
28 Lyzwinski LN, Eisenberg MJ. E-cigarette Polysubstance Vaping in Youth. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-92392-1_38] [Reference Citation Analysis]
29 Nazarov O, Li G. Linking Cannabis and Homicide: Comparison with Alcohol. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-92392-1_77] [Reference Citation Analysis]
30 Lyzwinski LN, Eisenberg MJ. E-cigarette Polysubstance Vaping in Youth. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-67928-6_38-2] [Reference Citation Analysis]
31 Lyzwinski LN, Eisenberg MJ. E-cigarette Polysubstance Vaping in Youth. Handbook of Substance Misuse and Addictions 2022. [DOI: 10.1007/978-3-030-67928-6_38-1] [Reference Citation Analysis]
32 Pérez Martínez J. Aspectos prácticos de la elección del producto y la titulación con cannabis medicinal para el dolor crónico. Rev Soc Esp Dolor 2022. [DOI: 10.20986/resed.2022.4031/2022] [Reference Citation Analysis]
33 Grimaldi JAR, Bodnar J, Lavin DR, Mclaughlin ML, Rasimas JJ, Ashley K. Substance-Related and Addictive Disorders. HIV Psychiatry 2022. [DOI: 10.1007/978-3-030-80665-1_11] [Reference Citation Analysis]
34 Patel D. Cannabis Use Disorder. Psychiatry Update 2022. [DOI: 10.1007/978-3-030-86430-9_4] [Reference Citation Analysis]
35 Zawilska JB, Kuczyńska K, Bratzu J, Fattore L. Neurotoxicity of Exogenous Cannabinoids. Handbook of Neurotoxicity 2022. [DOI: 10.1007/978-3-031-15080-7_206] [Reference Citation Analysis]
36 Čulić A, Bregar B, Macur M. Raba konoplje v medicinske namene: integrativni pregled literature. Obzor Zdrav Neg 2021;55. [DOI: 10.14528/snr.2021.55.4.3063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Addictions and Substance Misuse. The Maudsley Prescribing Guidelines in Psychiatry 2021. [DOI: 10.1002/9781119870203.mpg004] [Reference Citation Analysis]
38 Howard J, Wurzelbacher S, Osborne J, Wolf J, Ruser J, Chadarevian R. Review of cannabis reimbursement by workers' compensation insurance in the U.S. and Canada. Am J Ind Med 2021;64:989-1001. [PMID: 34532872 DOI: 10.1002/ajim.23294] [Reference Citation Analysis]
39 MacCamy K, Hu D. Dexmedetomidine for Treatment of Delayed Peak Symptoms of Cannabis Withdrawal Syndrome: A Case Report. Hosp Pharm 2021;56:462-5. [PMID: 34720146 DOI: 10.1177/0018578720919025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
40 Aviz-Amador A, Contreras-Puentes N, Mercado-Camargo J. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB1 and CB2 receptors. Comput Biol Chem 2021;95:107590. [PMID: 34700256 DOI: 10.1016/j.compbiolchem.2021.107590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
41 Bonnet U, Borda T, Scherbaum N, Specka M. Long-Term Frequent Cannabis Use and Related Serum Cannabinoid Levels Are Not Associated with Kidney Dysfunction. Cannabis Cannabinoid Res 2021. [PMID: 34704814 DOI: 10.1089/can.2021.0086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Schrott R, Murphy SK, Modliszewski JL, King DE, Hill B, Itchon-Ramos N, Raburn D, Price T, Levin ED, Vandrey R, Corcoran DL, Kollins SH, Mitchell JT. Refraining from use diminishes cannabis-associated epigenetic changes in human sperm. Environ Epigenet 2021;7:dvab009. [PMID: 34557312 DOI: 10.1093/eep/dvab009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
43 Springer SD, Spooner RK, Schantell M, Arif Y, Frenzel MR, Eastman JA, Wilson TW. Regular recreational Cannabis users exhibit altered neural oscillatory dynamics during attention reorientation. Psychol Med 2021;:1-10. [PMID: 34889178 DOI: 10.1017/S0033291721002671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Craft S, Ferris JA, Barratt MJ, Maier LJ, Lynskey MT, Winstock AR, Freeman TP. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis. Psychopharmacology (Berl) 2021. [PMID: 34533608 DOI: 10.1007/s00213-021-05945-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Coughlin LN, Ilgen MA, Jannausch M, Walton MA, Bohnert KM. Progression of cannabis withdrawal symptoms in people using medical cannabis for chronic pain. Addiction 2021;116:2067-75. [PMID: 33400332 DOI: 10.1111/add.15370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
46 Cooke ME, Gilman JM, Lamberth E, Rychik N, Tervo-Clemmens B, Evins AE, Schuster RM. Assessing Changes in Symptoms of Depression and Anxiety During Four Weeks of Cannabis Abstinence Among Adolescents. Front Psychiatry 2021;12:689957. [PMID: 34276449 DOI: 10.3389/fpsyt.2021.689957] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Narouze S, Strand N, Roychoudhury P. Cannabinoids-based Medicine Pharmacology, Drug Interactions, and Perioperative Management of Surgical Patients. Adv Anesth 2020;38:167-88. [PMID: 34106833 DOI: 10.1016/j.aan.2020.08.004] [Reference Citation Analysis]
48 Rehman Y, Saini A, Huang S, Sood E, Gill R, Yanikomeroglu S. Cannabis in the management of PTSD: a systematic review. AIMS Neurosci 2021;8:414-34. [PMID: 34183989 DOI: 10.3934/Neuroscience.2021022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Kichloo A, Albosta M, Aljadah M, El-Amir Z, Goldar G, Khan MZ, Dahiya DS, Vallabhaneni S, Wani F, Singh J. Marijuana: A systems-based primer of adverse effects associated with use and an overview of its therapeutic utility. SAGE Open Med 2021;9:20503121211000909. [PMID: 33786179 DOI: 10.1177/20503121211000909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Genrich G, Zeller C, Znoj HJ. Interactions of protective behavioral strategies and cannabis use motives: An online survey among past-month users. PLoS One 2021;16:e0247387. [PMID: 33647024 DOI: 10.1371/journal.pone.0247387] [Reference Citation Analysis]
51 Mazza M. Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series. J Cannabis Res 2021;3:4. [PMID: 33597032 DOI: 10.1186/s42238-021-00060-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Takakuwa KM, Schears RM. The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review. Int J Emerg Med 2021;14:10. [PMID: 33568074 DOI: 10.1186/s12245-021-00330-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Yazici AB, Guzel D, Kurt EM, Turkmen B, Yazici E. Klotho, BDNF, NGF, GDNF Levels and Related Factors in Withdrawal Period in Chronic Cannabinoid Users. Ind J Clin Biochem. [DOI: 10.1007/s12291-021-00959-0] [Reference Citation Analysis]
54 Breijyeh Z, Jubeh B, Bufo SA, Karaman R, Scrano L. Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses. Toxins (Basel) 2021;13:117. [PMID: 33562446 DOI: 10.3390/toxins13020117] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
55 Alsheikh MY. Post-Acute Withdrawal Syndrome: The Major Cause of Relapse among Psychoactive Substances Addicted Users. Arch Pharm Pract 2021;12:91-97. [DOI: 10.51847/ioicfujpnm] [Reference Citation Analysis]
56 Reichert RA, Silveira KM, Lopes FM, De Micheli D. Drug Abuse: Classifications, Effects and Risks. Behavior Analysis and Substance Dependence 2021. [DOI: 10.1007/978-3-030-75961-2_1] [Reference Citation Analysis]
57 Narouze SN, Maccallum CA, de Freitas L. Cannabis Use Disorder. Cannabinoids and Pain 2021. [DOI: 10.1007/978-3-030-69186-8_38] [Reference Citation Analysis]
58 Zawilska JB, Kuczyńska K, Bratzu J, Fattore L. Neurotoxicity of Exogenous Cannabinoids. Handbook of Neurotoxicity 2021. [DOI: 10.1007/978-3-030-71519-9_206-1] [Reference Citation Analysis]
59 Claus BB, Specka M, McAnally H, Scherbaum N, Schifano F, Bonnet U. Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor? Front Psychiatry 2020;11:598150. [PMID: 33343424 DOI: 10.3389/fpsyt.2020.598150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
60 Howard J, Osborne J. Cannabis and work: Need for more research. Am J Ind Med 2020;63:963-72. [PMID: 32797692 DOI: 10.1002/ajim.23170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
61 Moussa-Tooks AB, Larson ER, Gimeno AF, Leishman E, Bartolomeo LA, Bradshaw HB, Green JT, O'Donnell BF, Mackie K, Hetrick WP. Long-Term Aberrations To Cerebellar Endocannabinoids Induced By Early-Life Stress. Sci Rep 2020;10:7236. [PMID: 32350298 DOI: 10.1038/s41598-020-64075-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
62 Chung M, Abdi S. Cannabis in Oncology and Symptom Management. Cannabis in Medicine 2020. [DOI: 10.1007/978-3-030-45968-0_12] [Reference Citation Analysis]
63 Brooks E, Sørheim SE. Looking at Marijuana Through the Lens of Public Health. Cannabis in Medicine 2020. [DOI: 10.1007/978-3-030-45968-0_18] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Kumar S, Verma V, Kushwaha U, Calvello Hynes EJ, Arya A, Agarwal A. Prevalence and association of depression in in-patient orthopaedic trauma patients: A single centre study in India. J Clin Orthop Trauma 2020;11:S573-7. [PMID: 32774031 DOI: 10.1016/j.jcot.2019.12.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
65 Ladha KS, Manoo V, Virji AF, Hanlon JG, Mclaren-Blades A, Goel A, Wijeysundera DN, Kotra LP, Ibarra C, Englesakis M, Clarke H. The Impact of Perioperative Cannabis Use: A Narrative Scoping Review. Cannabis Cannabinoid Res 2019;4:219-30. [PMID: 31872058 DOI: 10.1089/can.2019.0054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
66 Moussa-tooks AB, Larson E, Gimeno AF, Leishman E, Bartolomeo LA, Bradshaw H, Green JT, O’donnell BF, Mackie K, Hetrick WP. Long-term aberrations to cerebellar endocannabinoids induced by early-life stress.. [DOI: 10.1101/830901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Lerner A, Klein M. Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. Brain Commun 2019;1:fcz025. [PMID: 32954266 DOI: 10.1093/braincomms/fcz025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
68 Fraguas-Sánchez AI, Torres-Suárez AI. Medical Use of Cannabinoids. Drugs 2018;78:1665-703. [PMID: 30374797 DOI: 10.1007/s40265-018-0996-1] [Cited by in Crossref: 108] [Cited by in F6Publishing: 81] [Article Influence: 27.0] [Reference Citation Analysis]
69 Chocron Y, Zuber J, Vaucher J. Cannabinoid hyperemesis syndrome. BMJ. [DOI: 10.1136/bmj.l4336] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
70 Vieira Ferreira J, Cabral Correa L, Castro da Costa D, Izabel da Silva Hage-melim L. Bioligands Acting on the Cannabinoid Receptor CB1 for the Treatment of Withdrawal Syndrome Caused by Cannabis sativa. Recent Advances in Cannabinoid Research 2019. [DOI: 10.5772/intechopen.82184] [Reference Citation Analysis]
71 Schneider M, Friemel CM, von Keller R, Adorjan K, Bonnet U, Hasan A, Hermann D, Kambeitz J, Koethe D, Kraus L, Leweke FM, Lutz B, Paul L, Pogarell O, Preuss U, Schäfer M, Schmieder S, Simon R, Storr M, Hoch E. Cannabiskonsum zum Freizeitgebrauch. Cannabis: Potenzial und Risiko 2019. [DOI: 10.1007/978-3-662-57291-7_3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Blaney D, Jackson AK, Toy O, Fitzgerald A, Piechniczek-buczek J. Substance-Induced Anxiety and Co-occurring Anxiety Disorders. Substance Use and the Acute Psychiatric Patient 2019. [DOI: 10.1007/978-3-319-23961-3_8] [Reference Citation Analysis]
73 Sidelnik SA, Benzer TI. Cannabis Use Disorders and Related Emergencies. Substance Use and the Acute Psychiatric Patient 2019. [DOI: 10.1007/978-3-319-23961-3_4] [Reference Citation Analysis]
74 Hämmig R, Preuss UW, Soyka M. Cannabis. Suchtmedizin 2019. [DOI: 10.1016/b978-3-437-23021-9.00009-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Clark TM, Jones JM, Hall AG, Tabner SA, Kmiec RL. Theoretical Explanation for Reduced Body Mass Index and Obesity Rates in Cannabis Users. Cannabis Cannabinoid Res 2018;3:259-71. [PMID: 30671538 DOI: 10.1089/can.2018.0045] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
76 Joseph C, Ojo O, Popoola O, Azizi H, Khan T, Pramanik O, Kahn A, Chaudhry S, Rimawi D, Singh M, Mallick A, Paul S, Ojimba C, Jolayemi A. A case of brief psychosis upon cannabis withdrawal. MOJAMT 2018;5. [DOI: 10.15406/mojamt.2018.05.00135] [Reference Citation Analysis]
77 Livne O, Shmulewitz D, Lev-Ran S, Hasin DS. DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. Drug Alcohol Depend 2019;195:170-7. [PMID: 30361043 DOI: 10.1016/j.drugalcdep.2018.09.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
78 Cousijn J, van Duijvenvoorde ACK. Cognitive and Mental Health Predictors of Withdrawal Severity During an Active Attempt to Cut Down Cannabis Use. Front Psychiatry 2018;9:301. [PMID: 30050473 DOI: 10.3389/fpsyt.2018.00301] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
79 Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci 2018;27:327-35. [PMID: 29789034 DOI: 10.1017/S2045796018000239] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
80 Japuntich SJ, Arditte Hall KA, Joos CM, Rasmusson AM, Pineles SL. Methods to reduce false reporting of substance abstinence in clinical research. Int J Methods Psychiatr Res 2018;27:e1603. [PMID: 29314410 DOI: 10.1002/mpr.1603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
81 Brezing CA, Levin FR. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Neuropsychopharmacology 2018;43:173-94. [PMID: 28875989 DOI: 10.1038/npp.2017.212] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 12.2] [Reference Citation Analysis]